Every material Form 8-K Neurocrine Biosciences has filed with the SEC since February 06, 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Neurocrine Biosciences reported third-quarter 2026 total revenues of $1.1 billion, representing 41% year-over-year growth, alongside GAAP net income of $207 million. The company also raised its full-year 2026 net sales guidance for INGREZZA to a range of $2.9 billion to $2.925 billion.
Total revenues for the third quarter of 2026 reached $1.1 billion, up 41% compared to $795 million in the third quarter of 2025.
INGREZZA net product sales were $801 million, leading management to raise full-year 2026 INGREZZA net sales guidance to $2.9 billion to $2.925 billion.
GAAP net income for the third quarter of 2026 was $207 million, or $1.96 per diluted share, compared to $210 million, or $2.04 per diluted share, in the prior-year period.
Neurocrine Biosciences appointed Eiry W. Roberts, M.D., as Chief Medical Officer effective September 28, 2026, succeeding Sanjay Keswani, M.D., whose service ended September 25, 2026 by mutual agreement. The filing says Dr. Roberts will receive a base salary of $825,000, a target bonus of 60% of base pay, and about $1.25 million in target equity grants, and that Dr. Keswani will receive severance under the company's Executive Severance Plan.
Dr. Keswani's service as Chief Medical Officer ended September 25, 2026, by mutual agreement with the Board.
Dr. Roberts was appointed Chief Medical Officer effective September 28, 2026, with an annual base salary of $825,000 and a target bonus of 60% of base pay for 2026.
Target equity grants total about $1.25 million: stock options of about $625,000, restricted stock units of about $250,000, and performance-vesting restricted stock units of about $375,000.
The final Employment Agreement is expected to be filed with the Form 10-Q for the quarter ending September 30, 2026.
Neurocrine Biosciences reported second-quarter 2026 revenue of $959 million, up 39% from $688 million a year earlier, with GAAP diluted earnings per share of $1.39 versus $1.06. The company raised its full-year 2026 INGREZZA net sales guidance to $2.825 billion to $2.875 billion from $2.7 billion to $2.8 billion, and it completed its Soleno Therapeutics acquisition in May 2026.
Total revenue was $959 million in Q2 2026 versus $688 million in Q2 2025.
GAAP net income was $144 million, or $1.39 per diluted share, versus $108 million, or $1.06, a year earlier.
INGREZZA full-year 2026 net product sales guidance was raised to $2.825 billion to $2.875 billion from $2.7 billion to $2.8 billion.
VYKAT XR net product sales were $54 million from May 18, 2026, the Soleno acquisition closing date.
At its annual meeting on May 27, 2026, Neurocrine Biosciences stockholders elected three Class III directors to three-year terms expiring at the 2029 meeting. They also approved an amendment to the 2025 Equity Incentive Plan, approved the compensation of named executive officers on an advisory basis, and ratified Ernst & Young LLP as the independent auditor for fiscal 2026. The plan amendment governs equity awards to employees and directors, and its material terms are described in the April 15, 2026 proxy statement.
Shares present were 90,118,625 of 100,581,991 entitled to vote as of the March 31, 2026 record date.
Amended 2025 Plan approved with 79,131,622 votes for, 5,568,926 against and 65,732 abstentions.
Advisory vote on executive pay passed with 78,993,894 votes for and 5,669,155 against.
Kevin C. Gorman, Ph.D. received 76,228,063 votes for; Gary A. Lyons received 75,278,705 and Johanna Mercier received 74,671,942.
Neurocrine Biosciences completed its acquisition of Soleno Therapeutics on May 18, 2026, through a $53.00 per share cash tender offer and merger. The deal adds VYKAT XR, a treatment for hyperphagia in Prader-Willi syndrome, to Neurocrine's commercial portfolio. The company funded the roughly $2.9 billion cash payment from cash on hand and also drew $600.0 million under a new $1.0 billion revolving credit facility.
Tender offer price of $53.00 per share in cash; 46,356,114 Soleno shares, about 88.9% of outstanding shares, were validly tendered by the May 15, 2026 expiration
Aggregate cash paid was approximately $2.9 billion plus fees and expenses, funded from Neurocrine's available cash on hand
New five-year, $1.0 billion senior secured revolving credit facility with JPMorgan Chase Bank, N.A. dated May 14, 2026; $600.0 million initial borrowing made on that date
Soleno common stock will no longer be listed or traded on the Nasdaq Capital Market as of May 18, 2026
Neurocrine Biosciences reported first-quarter 2026 total revenues of $814.5 million, up 42% from a year earlier, and GAAP diluted earnings of $1.91 per share versus $0.08 a year earlier. The company reaffirmed its 2026 INGREZZA net sales guidance of $2.7 billion to $2.8 billion and said it expects to close its $2.9 billion acquisition of Soleno Therapeutics in the second quarter of 2026.
Total net product sales were $811.0 million, up 44% year over year; INGREZZA contributed $656.9 million (up 20%) and CRENESSITY contributed $153.3 million, versus $14.5 million a year earlier.
GAAP net income was $197.9 million, or $1.91 per diluted share, compared with $7.9 million, or $0.08, in the first quarter of 2025.
Non-GAAP diluted EPS was $1.94, compared with $0.70 a year earlier.
Full-year 2026 INGREZZA net sales guidance of $2.7 billion to $2.8 billion was reaffirmed; the Soleno Therapeutics deal is at $53.00 per share in cash and is expected to close in Q2 2026.
Neurocrine Biosciences agreed on April 5, 2026 to acquire Soleno Therapeutics through a cash tender offer at $53.00 per share, a total equity value of $2.9 billion. The deal adds VYKAT XR, Soleno's approved treatment for hyperphagia in Prader-Willi syndrome, which generated $190 million of 2025 revenue, to Neurocrine's portfolio. The transaction is expected to close within 90 days, subject to customary conditions including regulatory approvals.
Offer price is $53.00 per Soleno share in cash, a premium of approximately 34% to the April 2, 2026 closing price
Transaction is funded with cash on hand plus a modest amount of pre-payable debt, and is not subject to a financing condition
VYKAT XR generated $190 million in 2025 revenue, including $92 million in the fourth quarter alone
Expected to close within 90 days of the April 6, 2026 announcement, subject to regulatory approvals and tender of a majority of Soleno shares
Neurocrine Biosciences reported fourth-quarter 2025 total revenues of $805.5 million, up from $627.7 million a year earlier, and GAAP diluted earnings per share of $1.48, up from $1.00. It also gave 2026 full-year guidance for INGREZZA net product sales of $2.7 billion to $2.8 billion, compared with $2.51 billion in 2025, which gives shareholders a revenue benchmark for the year ahead.
Q4 2025 total revenues were $805.5 million versus $627.7 million in Q4 2024; GAAP net income was $153.7 million versus $103.1 million.
Full-year 2025 net product sales were $2.83 billion, up 22%; CRENESSITY net product sales were $301.2 million versus $1.7 million in 2024.
2026 guidance: INGREZZA net product sales of $2.7 billion to $2.8 billion; GAAP R&D expense of $1.2 billion to $1.25 billion; GAAP SG&A expense of $1.375 billion to $1.4 billion.
Cash, cash equivalents, and marketable securities totaled approximately $2.54 billion at December 31, 2025.
Neurocrine Biosciences amended the employment agreement with Eiry W. Roberts, M.D., its former Chief Medical Officer, on November 21, 2025. The amendment extends her employment term by 12 months, to December 31, 2026. Sanjay Keswani, M.D. has served as Chief Medical Officer since June 2, 2025, so the change does not alter that role.
Amendment dated November 21, 2025 extends the term of employment by an additional 12 months, expiring December 31, 2026.
Sanjay Keswani, M.D. succeeded Dr. Roberts as Chief Medical Officer effective June 2, 2025.
Under the prior agreement, Dr. Roberts served as Strategic Advisor through December 31, 2025.
Full text of the amendment is filed as Exhibit 10.1.
Neurocrine Biosciences reported third-quarter 2025 results, with total net product sales of $790 million, up 28% from a year earlier, and GAAP diluted earnings per share of $2.04 versus $1.24. The company reaffirmed its full-year 2025 INGREZZA net product sales guidance of $2.5 billion to $2.55 billion and updated its R&D and SG&A expense ranges.
Total net product sales were $790 million for the quarter, up 28% year over year and 16% sequentially.
GAAP net income was $210 million ($2.04 per diluted share), compared with $130 million ($1.24) in the third quarter of 2024.
CRENESSITY net product sales were $98 million in the quarter, with 540 new patient enrollment start forms.
Full-year 2025 INGREZZA net product sales guidance of $2.5 billion to $2.55 billion was reaffirmed; GAAP R&D guidance is $1.0 billion to $1.02 billion.
Neurocrine Biosciences reported second-quarter 2025 net product sales of $682 million, up 17% year over year, and GAAP diluted earnings per share of $1.06 versus $0.63 a year earlier. The company narrowed its 2025 INGREZZA net product sales guidance to $2.5 billion to $2.55 billion from $2.5 billion to $2.6 billion, lowering the top of the range, and said a Phase 3 study of valbenazine in schizophrenia did not meet its primary endpoint.
Q2 2025 net product sales were $682 million: INGREZZA $624.4 million and CRENESSITY $53.2 million
GAAP net income was $107.5 million ($1.06 per diluted share) versus $65.0 million ($0.63) in Q2 2024; non-GAAP EPS was $1.65 versus $1.63
INGREZZA 2025 net product sales guidance narrowed to $2.5 billion to $2.55 billion from $2.5 billion to $2.6 billion
Company repurchased $18 million of stock in Q2 2025 and had $332 million remaining under its $500 million program as of June 30, 2025
Neurocrine Biosciences said Sanjay Keswani, M.D. will succeed Eiry W. Roberts, M.D. as Chief Medical Officer effective June 2, 2025. Dr. Roberts, who has held the role for seven years, will stay on as Strategic Advisor to the CEO through December 31, 2025 under an amended employment agreement with a $731,400 base salary.
Sanjay Keswani, M.D. succeeds Eiry W. Roberts, M.D. as Chief Medical Officer effective June 2, 2025
Dr. Roberts becomes Strategic Advisor to the CEO through December 31, 2025, with a $731,400 annual base salary
Dr. Roberts's target bonus is 60% of base pay for calendar year 2025; severance and outstanding equity awards carry over
At its May 21, 2025 annual meeting, Neurocrine Biosciences stockholders approved the 2025 Equity Incentive Plan and an amended and restated 2018 Employee Stock Purchase Plan, elected four Class II directors, and approved the advisory vote on executive compensation. Stockholders also ratified Ernst & Young LLP as the independent auditor for fiscal 2025. The filing reports the vote results, which are routine annual-meeting outcomes.
The 2025 Equity Incentive Plan was approved with 72,648,862 votes for and 12,884,104 against.
Four Class II directors were elected to three-year terms expiring at the 2028 annual meeting, including Richard F. Pops with 72,919,088 votes for.
Of 98,938,234 shares entitled to vote, 90,434,193 were present in person or by proxy.
Ernst & Young LLP was ratified as independent registered public accounting firm for the fiscal year ending December 31, 2025, with 85,019,349 votes for.
Neurocrine Biosciences reported first-quarter 2025 total revenues of $572.6 million, up from $515.3 million a year earlier, while GAAP diluted earnings per share fell to $0.08 from $0.42. The company reaffirmed its full-year 2025 INGREZZA net sales guidance of $2.5 billion to $2.6 billion, but higher R&D spending and a $30.6 million unrealized loss on equity investments reduced profit.
INGREZZA first-quarter net product sales were $545.2 million, compared with $506.0 million a year earlier; CRENESSITY sales were $14.5 million.
GAAP net income was $7.9 million, versus $43.4 million in Q1 2024; non-GAAP net income was $71.5 million, versus $124.8 million.
Q1 2025 R&D expense includes $45 million of development milestones, mainly tied to starting the osavampator Phase 3 program in major depressive disorder.
Cash, cash equivalents and marketable securities totaled $1,758.8 million at March 31, 2025, and $150 million of a $500 million buyback had been repurchased by that date.
Neurocrine Biosciences said Sanjay Keswani, M.D., will succeed Eiry W. Roberts, M.D., as Chief Medical Officer effective June 2, 2025. Dr. Roberts, who has held the role for seven years, will remain with the company in a strategic advisory role. The change replaces a long-serving clinical leader with an executive who has more than 20 years of pharmaceutical industry experience.
Sanjay Keswani, M.D., agreed on April 2, 2025 to become Chief Medical Officer, effective June 2, 2025
Dr. Keswani succeeds Eiry W. Roberts, M.D., who has served as CMO for the past seven years
Dr. Roberts previously announced her retirement in July 2023 and will stay on in a strategic advisory role
Dr. Keswani was previously President and CEO of ImmunoBrain and held R&D roles at Hoffmann-La Roche and Bristol-Myers Squibb
Neurocrine Biosciences reported fourth-quarter 2024 total revenues of $627.7 million, up from $515.2 million a year earlier, driven by INGREZZA net product sales of $615 million. GAAP net income fell to $103.1 million, or $1.00 per diluted share, from $147.7 million, or $1.44, as operating expenses rose, while non-GAAP diluted EPS rose to $1.69 from $1.54. The company also issued full-year 2025 INGREZZA net product sales guidance of $2.5 billion to $2.6 billion.
Q4 2024 total revenues $627.7 million vs. $515.2 million in Q4 2023; full-year 2024 total revenues $2,355.3 million vs. $1,887.1 million
Q4 2024 GAAP diluted EPS $1.00 vs. $1.44; non-GAAP diluted EPS $1.69 vs. $1.54, with the company citing $28 million of higher stock-based compensation tied to CRENESSITY approval and the CEO retirement charge
CRENESSITY fourth-quarter 2024 net product sales were $2 million, reflecting initial pharmacy orders after FDA approval in December 2024
Full-year 2025 guidance: INGREZZA net product sales of $2.5 billion to $2.6 billion; non-GAAP R&D of $890 million to $940 million and non-GAAP SG&A of $955 million to $975 million
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Neurocrine Biosciences filing is on SEC EDGAR ↗. 8-K briefs of other companies →